<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4426">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148430</url>
  </required_header>
  <id_info>
    <org_study_id>19-168</org_study_id>
    <nct_id>NCT04148430</nct_id>
  </id_info>
  <brief_title>A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy</brief_title>
  <official_title>A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells And to Treat Systemic Inflammation Associated With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to see if the investigational drug, anakinra, prevent or reverse the&#xD;
      severe side effects caused by CAR-T cell therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities</measure>
    <time_frame>4 weeks</time_frame>
    <description>Determine the rate of severe neurotoxicities, &gt;/= Grade 3 or any grade seizure, within the first 4 weeks of treatment with prophylactic use of anakinra in participants receiving CD19-specific CAR T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation</measure>
    <time_frame>28 days from the start of treatment</time_frame>
    <description>proportion of patients able to avoid death or mechanical ventilation within 28 days from the start of the treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>B Cell ALL</condition>
  <condition>B-Cell Lymphoma</condition>
  <condition>B-cell Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1 (CART Cell Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days.&#xD;
Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (COVID-19 Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive anakinra 100mg IV q6h for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>100mg subcutaneous</description>
    <arm_group_label>Arm 1 (CART Cell Group)</arm_group_label>
    <arm_group_label>Arm 2 (COVID-19 Group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Arm 1 (CART Cell Group):&#xD;
&#xD;
          -  Patients (age &gt;/= 18) with a diagnosis of relapsed CD19+ B-cell ALL or NHL receiving&#xD;
             commercially approved CD19-specific CAR T cells (e.g. tisagenleuleucel and&#xD;
             axicabtagene) are eligible for the study&#xD;
&#xD;
        Arm 2 (COVID-19 Group):&#xD;
&#xD;
        Both Cohorts:&#xD;
&#xD;
          -  Age ≥ 18 years old, with underlying solid tumor or hematologic malignancies&#xD;
&#xD;
          -  A positive test for SARS-CoV2 virus in any specimen, or recent exposure to a known&#xD;
             COVID-19 positive contact, or belonging to a high risk demographic group (living&#xD;
             and/or working in high-risk setting)&#xD;
&#xD;
        Cohort 1:&#xD;
&#xD;
          -  Infilgrate on CXR or CT scan, AND&#xD;
&#xD;
          -  O2 saturation ≤ 93% on room air, or requiring supplemental oxygen, or respiratory rate&#xD;
             ≥ 30 breaths/min&#xD;
&#xD;
          -  Evidence of systemic inflammatory response as defined by presence of at least two of&#xD;
             the following:&#xD;
&#xD;
               -  Fever of ≥ 38C at any time point following suspected diagnosis, or&#xD;
&#xD;
               -  CRP &gt; 5 mg/dL, or&#xD;
&#xD;
               -  Ferritin &gt; 500 ng/mL&#xD;
&#xD;
               -  AST/ALT ≤ 5x ULN&#xD;
&#xD;
        Cohort 2:&#xD;
&#xD;
          -  On mechanical ventilation within 48 hours of starting study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Arm 1 and Arm 2:&#xD;
&#xD;
          -  Patients with uncontrolled systemic fungal and bacterial infections&#xD;
&#xD;
          -  Patients with known hypersensitivity to E. coli-derived proteins&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             (women who have undergone surgical sterilization or who have been postmenopausal for&#xD;
             at least 2 years are not considered to be of childbearing potential)&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
        Arm 2 (COVID-19 Group) only:&#xD;
&#xD;
          -  Concurrent JAK inhibitors and/or IL-6 inhibitors (tocilizumab, siltuximab, etc.) for&#xD;
             treatment of COVID-19 pneumonia are excluded but previous history or administration of&#xD;
             these agents are allowed and no washout time is needed.&#xD;
&#xD;
          -  History of or concurrent use of hydroxychloroquine, anti-viral drugs, antibiotics,&#xD;
             corticosteroids and convalescent plasma is allowed.&#xD;
&#xD;
          -  Patients receiving active chemotherapy or patients whose life expectancy is estimated&#xD;
             to be &lt;3 months in the opinion of investigators, strictly due to their cancer&#xD;
             diagnosis (i.e. not due to COVID-19) are excluded&#xD;
&#xD;
          -  Myelosuppressive chemotherapy is prohibited until clinical recovery (i.e. 1 or 2 on&#xD;
             the 7-category ordinal scale)&#xD;
&#xD;
          -  CrCl &lt;30 mL/minute&#xD;
&#xD;
          -  Treatment with any investigational agent is prohibited, except for investigational&#xD;
             SAR-Co-V2 anti-viral agents, through 28 days after the last dose of anakinra&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Park, MD</last_name>
    <phone>212-639-4048</phone>
    <email>parkj6@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bianca Santomasso, MD, PhD</last_name>
    <phone>646-888-2092</phone>
    <email>SantomaB@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Park, MD</last_name>
      <phone>212-639-4048</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

